GlassScriptPhysician profile
Millard L Tierce
NPI 1528230687
$8,781.33
in general payments reported to CMS, 2019-2025
31 companies · $2,482 in 2025
The $2,482 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $181 · 2021: $70.46 · 2022: $321 · 2023: $2,268 · 2024: $2,730 · 2025: $2,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,423 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,423.23 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,454.21 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $953.58 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $923.41 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $860.10 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $692.14 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $548.11 | 2023-2025 | |
| Blueprint Medicines Corporation | $498.58 | 2023-2025 | Ayvakit |
| Csl Behring | $473.28 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $447.40 | 2020-2025 | Takhzyro, Cuvitru, Cinryze |
| Biocryst US Sales Co., LLC | $329.34 | 2023-2025 | Orladeyo |
| Alk-Abello, INC | $213.84 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Pharming Healthcare, INC. | $204.41 | 2021-2025 | Ruconest |
| Genentech USA, INC. | $192.47 | 2019-2024 | Xolair |
| Pfizer INC. | $164.80 | 2023-2025 | |
| Kaleo, INC. | $131.13 | 2023 | Auvi-Q |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116.61 | 2022-2023 | Rinvoq |
| Ars Pharmaceuticals Operations, INC. | $70.88 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $61.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Organon LLC | $55.70 | 2025 | Vtama |
| Amgen INC. | $54.02 | 2024 | Tezspire |
| Shire North American Group INC | $48.04 | 2019 | |
| Optinose US, INC. | $40.33 | 2023 | |
| Lilly USA, LLC | $35.72 | 2024-2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $28.19 | 2025 | Dawnzera |
| Kedrion Biopharma, INC. | $26.58 | 2025 | Kedrab, Koate, Gammaked |
| Incyte Corporation | $24.86 | 2023 | Opzelura |
| Cycle Pharmaceuticals INC | $23.22 | 2025 | Sajazir |
| Octapharma USA, INC. | $19.64 | 2021 | |
| Galderma Laboratories, L.P. | $17.23 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $14.85 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millard Tierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.